Skip to main content

Table 5 Modeling phases and data partitions

From: Structure-activity models of oral clearance, cytotoxicity, and LD50: a screen for promising anticancer compounds

Phase Partitions/activity Oral Clearance LD50 Cytotoxicity
Phase I training set 348 of 435 (80%) 3,095 of 3,869 (80%) 4,000 of 8,983 (44%), chosen from 70%
  testing set 87 of 435 (20%) 774 of 3,869 (20%) 2,695 of 8,983 (30%)
Phase II training set 435 of 435 (100%) 3,869 of 3,869 (100%) 4,500 of 8,983 (50%), includes all positive labels